Are You Ready for the Annual Psychiatric Times World CME Conference?
At the Annual Psychiatric Times World CME Conference, an all-star lineup of presenters will share their latest research. Check out this preview of the full agenda.
The Long Shadow of the Towers
Statistical findings from longitudinal studies of mental health among 9/11 witnesses and first responders.
8 Ways to Observe the 20th Anniversary of 9/11
How can we remember those who lost their lives in the 9/11 attacks, and support the mental health of survivors and their families?
8 CMEs You Can Take Today
Our roundup of free CMEs features innovating strategies for diagnosing and addressing the neuropsychiatric signs of multiple sclerosis, the therapeutic potential of psilocybin, poststroke depression, and more.
Challenging Diagnoses, New Treatments, and Clinical Conundrums Discussed at Annual Meeting
The 2021 American Psychiatric Association Virtual Annual Meeting brought together leaders in psychiatry to discuss hot topics including diversity, COVID-19, mood disorders, and more.
Dreaming of New Treatments
Sleep problems are understudied, underdiagnosed, and undertreated.
A New Target for Intervention in Alzheimer Disease?
Gene expressions in microglia cells may explain why some of them are ineffective and allow dementia to progress.
Looking to the Future of MDMA-Assisted Psychotherapy
New research find altered states of consciousness may allow veterans and other patients with PTSD to face unspeakable experiences and find peace.
Fast-Acting Options for Mood Disorders and Psychiatric Emergencies
What treatments could handle both psychiatric emergencies and long-standings mental health conditions—in a hurry?
Expert Panel Ponders What It Takes To Be an Ethical Psychiatrist
What’s a psychiatrist to do? An APA ethics panel at the Annual Meeting considered various dilemmas, including possible conflicts between physicians’ obligations to individual patients and their obligation to promote the public good.
Is There a New Mechanism for Treating Depression?
Opening certain potassium channels in the brain reduces depressive symptoms and anhedonia.
How to Identify and Tackle Treatment-Resistant Depression in Geriatric Patients
If patients decline electroconvulsive therapy, psychiatrists still have many good options.
Is the First Disease-Modifying Therapy for Alzheimer Disease on the Horizon?
Aducanumab is named 1 of the 5 “Drugs to Watch” for 2021.
How Will Patients React to Medications? The Answer May Be in Their Genes
A study finds that testing genetic variations can predict outcomes and medication blood levels in patients with depression.
A Potential Schizophrenia Treatment Trial Falls Short
Is this phase 2 trial the end of the road for a potential new treatment?
Hope for Dementia-Related Psychosis
A new treatment for hallucinations and delusions in individuals with Alzheimer disease may be on the horizon.
FDA Recalls A Pair of Drugs Due to a Packaging Mix-Up
Sildenafil and trazodone were inadvertently bottled together, posing serious health risks to consumers.
Blood Pressure Drug Benefits Patients Recovering From Alcohol Addiction
A drug developed to treat high blood pressure has unexpected benefits for patients with severe withdrawal symptoms.
A new study finds that isolation makes us want company on a neural level, in much the same way that hunger makes us want food.
A New Digital Therapeutic for Chronic Insomnia
Potential relief for millions of Americans with pandemic-related sleep issues.
Beyond the Presidential Race: Voters Address Mental Health Issues
In addition to choosing a president and other political leaders, Americans cast their votes on a host of issues relevant to psychiatrists.
2 Clarke Drive Cranbury, NJ 08512